Lung Cancer in Canada
Authors:
- 1 July 2019
- journal article
- editorial
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (7) , 1128-1133
Abstract
No abstract availableFunding Information
- Genzyme
- Eisai
- Merck
- Pfizer
- Bristol-Myers Squibb
- Roche
- Lilly
- Bristol-Myers Squibb
- Merck
- Celgene
- Shire
- Lilly
- Novartis
- Olympus
This publication has 9 references indexed in Scilit:
- Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective studyThe Lancet Oncology, 2017
- The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program EfficiencyJournal of Thoracic Oncology, 2017
- Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening StudyChest, 2016
- Recommendations on screening for lung cancerCanadian Medical Association Journal, 2016
- Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the LiteratureThe Oncologist, 2015
- Probability of Cancer in Pulmonary Nodules Detected on First Screening CTNew England Journal of Medicine, 2013
- A look at the thoracic surgery workforce in Canada: how demographics and scope of practice may impact future workforce needsCanadian Journal Of Surgery, 2013
- The effect of regionalization on outcome in pulmonary lobectomy: A Canadian national studyThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Standards for Thoracic Surgical Oncology in a Single-Payer Healthcare SystemThe Annals of Thoracic Surgery, 2007